Research and Markets: Triple Analysis: Breast Cancer, Leukemia and Apoptosis 2010 analyses 207 Identified Targets of Breas

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/abaa3a/triple_analysis_b) has announced the addition of the "Triple Analysis: Breast Cancer, Leukemia and Apoptosis" report to their offering.

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Leukemia and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Breast Cancer The breast cancer report part comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug target strategies, and assesses them in breast cancer.

This part is based on the following publication: Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place

Part II: Leukemia The leukemia report part comprises defined and up to date development strategies for 175 leukemia drugs (>250 projects) within the portfolio of 126 investigators, from Preclinical to Marketed. Leukemia drugs are further dived into the sub-indications of ALL, AML, CLL, CML, HCL and MCL. This report part extensively analyses 136 identified targets of leukemia drugs, organized into 115 drug target strategies, and assesses them in leukemia. This part is based on the following publication: Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking

Part III: Apoptosis The apoptosis report part comprises defined and up to date development strategies for 171 apoptotic drugs in oncology (519 projects) within the portfolio of 125 investigators, from Ceased to Pre-registration. This report part extensively analyses 146 identified targets of apoptotic drugs, organized into 120 drug target strategies, and assesses them in 53 different cancer indications. This part is based on the following publication: Apoptotic Therapeutics in Oncology - Where to Commercialize?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies pipeline and portfolio planning (PPP) in cancer by:

  • Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
  • Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drugs properties
  • Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
  • Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
  • Supporting development of integrative molecule, pathway and disease area strategies
  • Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

  • Part I: Breast Cancer
  • 5.1 The Scope of this Report 29
  • 6 Consider the Therapeutic Breast Cancer Target for the Highest Therapeutic Outcome and Return on Investment (207 Drug Targets) 33-376
  • 7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Strategies Identified in the Breast Cancer Therapeutic Pipeline? (193 Drug Target Strategies and 405 Drugs) 377-441
  • 8 Compound Strategies at Work: Competitive Benchmarking of Breast Cancer Drugs by Compound Strategy (8 Different Compound Strategies) 442-488
  • 9 Pipeline and Portfolio Planning: Competitive Benchmarking of Breast Cancer Therapeutic Pipeline by Investigator (220 Investigators) 489-891
  • 11 Drug Index 893
  • 12 Company Index 905
  • Figures: Includes 7 Figures
  • Tables: Includes 274 Tables
  • Part II: Leukemia
  • 5 Introduction 22
  • 6 Single Drug Target Benchmarking from the Leukemia Pipeline (136 Drug Targets) 25-265
  • 7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Combinations Identified in the Leukemia Pipeline? (115 Drug Target Strategies and 175 Drugs) 266-293
  • 8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Pipeline by Type of Compound (7 Different Compound Strategies) 294-324
  • 9 Portfolio Planning: Competitive Benchmarking of Leukemia Pipeline by Investigator (126 Investigators) 325-513
  • 11 Drug Index 515
  • 12 Company Index519
  • Figures: Includes 7 Figures
  • Tables: Includes 156 Tables
  • Total Number of Pages:
  • Part III: Apoptosis
  • 5.1 The Scope of this Report
  • 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (146 Drug Targets) 32-276
  • 7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Apoptotic Therapeutic Pipeline? (120 Drug Target Strategies and 171 Drugs)
  • 8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Drugs in Oncology by Compound Type (7 Different Compound Strategies)
  • 9 Selecting Cancer Indications for Apoptotic Therapeutics (53 Cancer Indications) 356-440
  • 10 Portfolio Planning: Competitive Benchmarking of Apoptotic Cancer Therapeutic Pipeline by Investigator (125 Investigators)
  • 12 Drug Index
  • 13 Company Index

For more information visit http://www.researchandmarkets.com/research/abaa3a/triple_analysis_b



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo